Mind Medicine (MNMD) has released an update.
Mind Medicine (MindMed) Inc. is set to present its phase 2b study results on MM120 for Generalized Anxiety Disorder at two major medical conferences in May 2024, highlighting innovative research and the impact of GAD on the US population. The presentations will cover the treatment’s rapid and durable response, the epidemiology of undiagnosed GAD, and its health-related quality of life implications.
For further insights into MNMD stock, check out TipRanks’ Stock Analysis page.
